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Abstract
Surveillance of HIV/AIDS mortality is crucial to evaluate a country’s response to the disease. With a modified estimation
approach, this study aimed to provide more accurate estimates on deaths due to HIV/AIDS in Iran from 1990 to 2015 at
national and sub-national levels. Using a comprehensive data set, death registration incompleteness and misclassification were
addressed by demographical and statistical methods. Trends of mortality due to HIV/AIDS at national and sub-national levels
were estimated by applying a set of models. A total of 474 men (95% uncertainty interval [UI]: 175–1332) and 256 women
(95% UI: 36–1871) died due to HIV/AIDS in 2015 in Iran. Peaked in 1995, HIV/AIDS-related mortality has steadily declined
among both genders. Mortality rates were remarkably higher among men than women during the period studied. At the sub-
national level, the highest and the lowest annual percent change were found at 10.97 and 1.36% for women, and 4.04 and
3.47% for men, respectively. The findings of our study (731 deaths) were remarkably lower than the Joint United Nations
Programme on HIV and AIDS (4000) but higher than Global Burden of Disease (339) estimates in 2015. The overall decrease
in mortality due to HIV/AIDS may be attributed to the increasing burden of noncommunicable diseases; however, the role of
the national and international organizations to fight HIV/AIDS should not be overlooked. To decrease HIV/AIDS mortality
and to achieve international goals, evidence-based action is required. To fast-track targets, the priority must be to prevent
infection, promote early diagnosis, provide access to treatment, and to ensure treatment adherence among patients.
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Introduction
With the advent of new regimens of antiretroviral ther-
apy (ART), HIV/AIDS-related mortality has declined
remarkably over the past decade in the world.1,2
Despite the recent achievements, HIV/AIDS is still
the leading cause of death in some countries, with an
estimated 1.2 million deaths in 2015.3 Lack of counsel-
ing and testing facilities,4 reluctance to be tested due to
stigma and discrimination,5 late diagnosis,6 as well as
barriers impeding ART access, including lack of
healthcare providers, overcrowded clinics, and distance
to the facilities7 are possible reasons for the constantly
high mortality due to HIV/AIDS in the world.
While ART can prevent HIV replication and pro-
gression to AIDS, it does not completely eliminate the
virus.8 Patients who receive treatment may have ongo-
ing reduced CD4 cell counts and may also die from
non-AIDS comorbidities such as cardiovascular,
hepatic, and pulmonary diseases, as well as non-
AIDS malignancies.9,10 Secondary morbidities due to
the adverse effects of ARTs, as well as age-related dis-
eases because of the longer survival are among the
other possible causes of death among people living
with HIV (PLWH).11
United Nations Programme on HIV/AIDS
(UNAIDS) is determined to end AIDS epidemic by
2030.12 To achieve this goal, UNAIDS has introduced
the so-called 90–90–90 targets: 90% of PLWH should
know their status, 90% of diagnosed cases should
receive ART, and 90% of patients on treatment
should have a suppressed viral load by 2020.13 By
achieving these targets, almost three quarters of
PLWH will have a suppressed viral load13 and HIV
mortality will decrease considerably over time.
However, turning this vision into reality requires con-
crete action to encourage people – in particular the
most at-risk populations, including people who inject
drugs, men who have sex with men, female sex workers
(FSWs), and prisoners – to be tested, to provide or
expand affordable and accessible treatment, and to
facilitate adherence to treatment among patients.
Surveillance of HIV mortality is crucial to evaluate a
country’s response to the disease and progress toward
the goals set forth by the global community. The
Global Burden of Disease (GBD) study and
UNAIDS are two main sources that estimate trends
in HIV/AIDS mortality in 195 countries. However,
the results of these two estimation approaches contra-
dict each other. Based on the GBD, the number of
deaths due to HIV in Iran was estimated to be 339
(95% uncertainty interval [UI]: 192–614) in 2015,14
which is much lower than the estimate of the
UNAIDS of 4000 deaths (95% CI: 2700–6000) in the
same year.15
In addition to the different findings, GBD and
UNAIDS have provided data on HIV/AIDS mortality
only at a national level for Iran. The present study
attempted to apply a modified method to enhance the
reliability of the estimated figures on deaths due to
HIV/AIDS in Iran from 1990 to 2015, and to provide
results at national and – for the first time – sub-
national levels.
Methods
Study design
Mortality data presented in this study were extracted
from the National and Sub-National Burden of
Diseases, Injuries, and Risk Factors study 2015
(NASBOD 2015).16 The NASBOD study is a system-
atic method to calculate the burden of 291 diseases and
67 risk factors for both genders. The 19 age groups
included in the study range from less than one-year-
old to 85 years or older, representative of both national
and sub-national populations within Iran. Materials
and methods applied to estimate the level and trend
of mortality for children and adults, and pattern of
cause of death have been discussed elsewhere in
detail.17–19 In this study, we aim to report the epidemi-
ologic trend of mortality rates by gender, age, and geo-
graphical distribution in Iran from 1990 to 2015.
Data collection
Within this study, two main sources of data were used:
the Iran Ministry of Health death registration system
(DRS) and individual data recorded by cemeteries in
Tehran and Esfahan. With a combined population of
over ten million, these two cities account for over 10%
of Iran’s total population. To standardize results
between the NASBOD study and the GBD, the
International Classification of Diseases 10th revision
(ICD-10) codes for cause of mortality were converted
to the GBD 2010 codes. Urbanization ratio and demo-
graphic measures for both genders, and 31 provinces,
were extracted from the national censuses conducted by
the Statistical Center of Iran (SCI).20 To estimate mor-
tality rates, we used covariates such as the total years of
schooling and the wealth index. The wealth index was
calculated from household expenditure and income
surveys between 1990 and 2015, conducted by SCI.
Data preparation and statistical analyses
We applied demographic and statistical models to
address incompleteness and misclassification of the
DRS data set. The NASBOD study contained two
parts for estimating mortality: the level and trend of
mortality rates. These two parts addressed the
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incompleteness of the DRS and causes of death, iden-
tifying misclassifications within the DRS. The first step
involved removing duplicate data that occurred mostly
due to the differences between the place of residence
and the place of death. During the next stage, missing
values were imputed by multiple imputation method
using the Amelia package in version 3.1.2 (R
Foundation for Statistical Computing; Vienna,
Austria) R software and multinomial imputation
model using STATA (StataCorp LP, TX, USA) soft-
ware version 11. Following this, a team of expert physi-
cians then converted ICD-10 codes to the GBD 2010
codes, considering age/gender restrictions, in addition
to redistributing garbage codes and ill-
defined codes.21,22
Incompleteness of the DRS data was addressed by
demographic and death distribution models. To esti-
mate child mortality, the complete birth history and
summary birth history (SBH) considered. To calculate
SBH, the maternal age cohort and maternal age period
methods were combined with LOESS regression. The
generalized growth balance (GGB), synthetic extinct
generation (SEG), and a mixture of the two methods
(GGE–SEG) were used to calculate the incompleteness
of adult mortality. More detailed information on this
model has been reported previously.17,19
Statistical models were used to interpolate and
extrapolate the child and adult mortality rates during
the study period. By applying a two-stage model, incor-
porating spatio-temporal and Gaussian process regres-
sion (GPR), the level and trend of child, adult, and all
age–gender specific mortality rates were calculat-
ed.17,18,23 The spatio-temporal model addressed the
problem of misalignment in age, space, and time of
the data considering the correlations among adjacent
years and provinces. GPR as a Bayesian was applied to
unify all data sources with a more reliable UI both
cross-sectionally and over time.
Cause-specific mortality was calculated by dividing
the above-mentioned cause fractions to total mortality
rates. In order to estimate UIs, the 2.5th and 97.5th
percentiles of 1000 spatio-temporal models were con-
sidered as lower and upper bounds, respectively. More
detailed information is available elsewhere.18 Iran’s
total population in 2015 was considered as the standard
population in the direct age-standardized approach to
facilitate the statistical comparisons between provinces.
Ethical considerations
The present study has been conducted following the
entire aspects of Helsinki declaration on ethics in med-
ical research. The data were anonymous, and the study
was approved by the ethics committee of
Endocrinology and Metabolism Clinical Sciences
Institute of Tehran University of Medical Sciences.
HIV mortality estimation
To analyze the HIV/AIDS mortality data, two GBD
codes – (1) HIV disease resulting in ‘mycobacterial
infection’ and (2) HIV disease resulting in ‘other speci-
fied or unspecified diseases’ – were combined and con-
sidered as one outcome. Due to the lack of data for
people aged 75 and older, we estimated the main out-
come for people in 16 age groups from under one-year-
old to 74 years of age. National and sub-national levels
and trends of death due to HIV/AIDS are presented
in the tables and figures designed by R software
version 3.1.2.
Results
In 2015, a total of 474 (95% UI: 175–1332) men and
256 (95% UI: 36–1871) women died from HIV/AIDS
in Iran, accounting for 0.17 and 0.21% of the total
deaths for Iranian women and men, respectively
(Table 1). Of the 165 causes of death studied in
NASBOD, in 1990 HIV/AIDS was ranked 92nd.
However, between 1990 and 2015, an increase in the
number of deaths due to HIV/AIDS was observed for
both genders. This increase has resulted in HIV/AIDS-
related deaths now being considered the 69th cause of
death out of the 165 causes of death studied.
Within age demographics, the highest mortality rate
per 100,000 related to HIV/AIDS was observed among
male children aged 1–4 years in 1990, and males aged
between 55 and 59 years in 2015 (Figure 1, supplemen-
tary Appendix 1).
National estimates for HIV/AIDS-related deaths
ranked 16th between 1990 and 1996, and then dropped
Table 1. All ages mortality due to HIV/AIDS in 1990, 1995, 2000, 2005, 2010, and 2015 by gender at national level.
Gender
Year
1990 1995 2000 2005 2010 2015
Both 449 (106–2441) 605 (159–2905) 625 (182–2622) 667 (210–2591) 725 (228–2871) 731 (212–3203)
Female 77 (7–1006) 142 (18–1340) 174 (27–1248) 198 (35–1253) 220 (36–1488) 256 (36–1871)
Male 372 (99–1435) 463 (142–1565) 451 (156–1374) 469 (175–1338) 505 (192–1382) 474 (175–1332)
Data in parentheses are 95% uncertainty intervals.
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to 21st place between the period of 2010–2015.
The national and sub-national ranks of age- and
sex-standardized death rates related to HIV/AIDS
between 1990 and 2015 are presented in Figure 2.
Age-standardized mortality rates due to HIV/
AIDS were higher among males than females at the
national level during the period of study (Figure 3,
Table 2). At sub-national level, the highest mortality
Figure 1. HIV/AIDS mortality rate per 100,000 in 1990 and 2015 in both genders by age groups in Iran.
Figure 2. Trends in mortality rates due to HIV/AIDS by province from 1990 to 2015 in Iran*.
*The two-digit codes mentioned in legend and in the figure are Hierarchical Administrative Subdivision Codes (HASC) of Iranian
provinces from which “IR.” has been eliminated in order to avoid repetition.
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rates among men were 2.79 and 3.53, and the lowest
were 0.16 and 0.25 in 1990 and 2015, respectively.
Among women, the highest and lowest sub-national
death rates were 1.44 and 0.02 in 1990, and 2.21 and
0.13 in 2015, respectively (Table 2, supplementary
Appendix 2).
At the sub-national level, the highest and lowest annual
percent changes were found at 10.97 and 1.36% for
women, and 4.04 and 3.47% for men, respectively.
The annual percentage change in rates during 1990–2015
by gender is presented in Table 2.
In Figure 4, the provincial patterns of age-
standardized death rates per 100,000 related to HIV/
AIDS in the years 1990 and 2015 are presented by
gender. Based on the sub-national patterns, in 1990,
higher mortality rates were observed in border provin-
ces in comparison to central provinces among both
genders. The highest growth has been observed in the
southern provinces during the study period.
Discussion
In Iran for the year 2015, an estimated 731 deaths
occurred due to HIV/AIDS. This figure is substantially
lower than UNAIDS’s estimate of 4000, but higher
than GBD’s estimation of 339. After reaching its
peak in 1995, overall HIV/AIDS mortality rates in
Iran have steadily declined. Excluding PLWH aged
over 65 years, the rates were remarkably higher
among men than women in all other age groups in
2015. Despite the considerable decrease in under-five
mortality, HIV/AIDS mortality rates ascended among
the 15- to 49-year-old age group during the period
of study.
A remarkable disparity was noted between the
number of registered deaths given as 470, and the
4000 estimated deaths reported by UNAIDS in
2015.15 Although major differences are observed
between the outcome of our study and the UNAIDS
estimates, both studies show a dramatic increase in
number of deaths due to HIV among women between
1990 and 2015 in Iran. UNAIDS has recently modified
its methodology through addressing the issue of ‘loss to
follow-up’ in estimating deaths among PLWH receiv-
ing ART.24 By modifying the methodology, the gap
between the estimates resulting from the method
applied in our study and the UNAIDS estimates may
be smaller in the future.
Among the available methods used to estimate HIV-
related outcomes, the Spectrum computer package is
the best-known program, widely used in many coun-
tries all around the world.25 The UNAIDS has used the
findings of Spectrum and its modeling to compile the
estimates worldwide.26 For more than a decade,
Spectrum has provided estimations for different key
HIV outcomes, most importantly including the
number of PLWH, new infections, and deaths due to
AIDS.25 The results stemmed from the Spectrum
modeling have usually been used for planning intents
and advocacy purposes usually for a short period of
time since new updates to calibrate the previous esti-
mates are quite often released. Data used in this pro-
gram are based on the demographic inputs, fertility,
and mortality; HIV prevalence data from several sur-
veillance surveys for different key affected populations
and general population (i.e. HIV cases from pregnant
women); and other supplementary information which
might be different in each country.26 The estimated
number of death due to HIV infection in 2015 provided
by Spectrum was 400015; however, the estimated statis-
tics from this program has not been well validated com-
pared with empirical data.3
Compared to the UNAIDS, our findings are better
aligned with the results of the GBD study, although the
estimation of the GBD was still lower in terms of
the absolute numbers. According to the GBD in
2016, the number of deaths due to HIV/AIDS in Iran
increased from 21 in 1990 to 339 in 2015 for both gen-
ders.14 However, in terms of gender difference, the
GBD indicated that deaths among women accounted
for only 14% of total deaths due to HIV/AIDS in 2015
in Iran. Yet, HIV/AIDS mortality rates among women
in our study were estimated higher at 35%, instead of
14% within the same time period. Despite these differ-
ences, both studies confirm that male HIV/AIDS mor-
tality rates between 1990 and 2015 were remarkably
higher than those for women in Iran.
Despite our robust methodology, findings of this
study should be interpreted in view of the study
Figure 3. Mortality rate due to HIV/AIDS from 1990 to 2015 in
males, females, and both genders in Iran.
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limitations. There were some calculation limitations in
the NASBOD study which have been described else-
where in detail.19 In addition, in the NASBOD study,
only three main covariates including wealth index,
years of schooling, and urbanization were entered to
enhance the statistical models. The inclusion of addi-
tional covariates could have led to better estimations.
In our study, all causes of death related to HIV/
AIDS have been combined and reported as one out-
come, while the GBD study has categorized mortality
due to HIV/AIDS into four sub-categories as follows:
drug-susceptible HIV/AIDS-tuberculosis, multidrug-
resistant HIV/AIDS-tuberculosis, extensively drug-
resistant HIV/AIDS-tuberculosis, and HIV/AIDS
resulting in other diseases. Addressing the above-
mentioned limitation appears necessary to produce
better estimations in the future.
Although HIV/AIDS mortality rates among Iranian
women have been decreasing, this reduction is consid-
erably slower than for men. In contrast to the rate, the
absolute number of deaths due to HIV among women
in Iran nearly tripled over the period of study.
Furthermore, at the sub-national level, the highest
positive annual percentage change was remarkably
higher among women (10.97%) than men (4.04%).
This may be explained by the interventional lack of
attention to the specific physical and socio-economic
characteristics within which HIV/AIDS morbidity is
embedded such as stigma, gender norms, and policies
that result in the unavailability, inaccessibility, or lack
of willingness to use interventions such as treatment,
care, and support for the most at-risk women such as
FSWs and prisoners.27 Methadone maintenance treat-
ment (MMT), which was launched in women’s prisons
long after it was available for men in Iran, is an exam-
ple of this inequality.27 Community-based women-only
MMT programs were also slow to start in Iran.28 The
increased risk of death associated with pregnancy/post-
partum complications among HIV-positive women29 is
another potential reason for the increase in the number
of deaths due to HIV/AIDS among Iranian women.
The noted lack of attention to the sexual and reproduc-
tive health needs of HIV-positive women in Iran30 fur-
ther supports this hypothesis.
Three out of four Iranian provinces with the highest
HIV mortality rates in 2015 share a border with
Figure 4. HIV/AIDS-related mortality rate per 100,000 by gender and province in 1990 and 2015.
Moazen et al. 1369
neighboring countries where there is higher prevalence
of drug use and HIV/AIDS. These countries corre-
spondingly record a higher prevalence of drug use in
addition to major infectious diseases and associated
risk factors.21–33 Iran is also one of the main routes
of drug trafficking, sharing a border with
Afghanistan and Pakistan, two of the largest producers
of illicit drugs in the world.34 Although no study has
evaluated epidemiology, nor possible predictors of
HIV/AIDS transmission among people living in
border areas of Iran, higher mortality due to HIV/
AIDS in these areas may be related to drug issues.
Population-based studies should be designed and con-
ducted to prove this hypothesis.
A systematic analysis of the global trend of mortal-
ity for 264 causes of death from 1990 to 2016 showed a
remarkable growth in mortality rates due to noncom-
municable diseases (NCDs) estimated at 72.3% of total
deaths in 2016.35 Following the same pattern, the
burden of NCDs is also considerably increasing in
Iran,36,37 most likely due to the rise in dietary and met-
abolic risk factors, tobacco smoking, air pollution, and
low physical activity.38 As a possible scenario, the over-
all decrease in mortality rates due to HIV/AIDS may
have been as a result of an excessive growth in the
burden of NCDs during the past three decades in Iran.
The role of national and international organizations
in the fight against HIV/AIDS transmission should not
be underestimated. During the recent years, a set of
joint and harmonized activities has been coordinated
by the Ministry of Health, international organizations,
and NGOs to reduce the burden of HIV/AIDS and the
related infections in Iran. More attention has been paid
to the most at-risk populations by providing services
such as information, education, and risk communica-
tion; voluntary counseling and testing; as well as treat-
ment, care, and support. Today, these services are
being offered free of charge through harm-reduction
centers around the country. Scaling up and strengthen-
ing comprehensive prevention interventions, as well as
improving the quality and coverage of the existing serv-
ices would guarantee the achievement of the goals set
forth by the international organizations in the future.
Conclusions
The present study is the first of its kind in Iran to esti-
mate deaths due to HIV/AIDS at sub-national level,
presented by gender and age groups during the period
1990–2015. Findings of our study were remarkably
higher than the GBD and lower than UNAIDS esti-
mates. Higher positive APC and increasing number of
deaths due to HIV/AIDS among Iranian women are a
cause for concern, highlighting the need for gender-ori-
ented interventions to address the issue urgently.
Higher rates of mortality due to HIV/AIDS in border
provinces need to be scrutinized and addressed as well.
To reach the international goals such as the so-called
90–90–90 objective by the UNAIDS, evidence-based
interventions are needed to promote the early diagnosis
of HIV/AIDS, provide access to treatment, and to
ensure treatment adherence especially among the
most at-risk populations in Iran. Such interventions
would not be successful without considering the role
of age, ethnicity, culture, and socio-economic status
of the target populations.
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